최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0256925 (2010-08-20) |
등록번호 | US-9919072 (2018-03-20) |
국제출원번호 | PCT/US2010/046209 (2010-08-20) |
§371/§102 date | 20111004 (20111004) |
국제공개번호 | WO2011/022680 (2011-02-24) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 276 |
Provided according to some embodiments of the invention are wound dressings that include a polymer matrix and nitric oxide-releasing polysiloxane macromolecules within and/or on the polymer matrix. Also provided are wound dressing kits and methods of using and forming such wound dressings.
1. A wound dressing comprising a polymer matrix, and nitric oxide (NO)-releasing polysiloxane macromolecules within the polymer matrix,wherein the NO-releasing polysiloxane macromolecules are NO-releasing particles that have a molar mass of at least 500 Da and a diameter in a range of 0.1 nm to 100
1. A wound dressing comprising a polymer matrix, and nitric oxide (NO)-releasing polysiloxane macromolecules within the polymer matrix,wherein the NO-releasing polysiloxane macromolecules are NO-releasing particles that have a molar mass of at least 500 Da and a diameter in a range of 0.1 nm to 100 μm, and the polymer matrix comprises a polyurethane foam, andwherein the wound dressing is non-toxic and stably stores NO. 2. The wound dressing of claim 1, wherein the NO-releasing polysiloxane macromolecules comprise N-diazeniumdiolate functional groups. 3. The wound dressing of claim 1, wherein the NO-releasing polysiloxane macromolecules comprise S-nitrosothiol functional groups. 4. The wound dressing of claim 1, wherein the NO-releasing polysiloxane macromolecules are present at a concentration in a range of about 0.1 to about 20 weight percent of the polymer matrix. 5. The wound dressing of claim 1, further comprising a water-soluble porogen selected from the group consisting of sodium chloride, sucrose, glucose, lactose, sorbitol, xylitol, polyethylene glycol, polyvinylpyrrollidone, polyvinyl alcohol and mixtures thereof. 6. The wound dressing of claim 1, further comprising at least one therapeutic agent selected from the group consisting of antimicrobial compounds, anti-inflammatory agents, pain-relievers, immunosuppressants, vasodilators, wound healing agents, anti-biofilm agents and mixtures thereof. 7. The wound dressing of claim 1, wherein the polyurethane foam comprises at least one polyisocyanate segment and at least one polyol segment. 8. The wound dressing of claim 7, wherein the at least one polyisocyanate segment is formed from a polyisocyanate selected from the group consisting of tolylene diisocyanate, methylphenylene diisocyanate, modified diisocyanates, and mixtures thereof. 9. The wound dressing of claim 7, wherein the at least one polyol segment is formed from at least one diol having from 2 to 18 carbon atoms. 10. The wound dressing of claim 9, wherein the at least one diol having from 2 to 18 carbon atoms is selected from the group consisting of 2-ethanediol, 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol, 1,5-pentanediol, 1,10-decanediol, 2-methyl-1,3-propanediol, 2-methyl-2-butyl-1,3-propanediol, 2,2-dimethyl-1,3-propanediol, 2,2-dimethyl-1,4-butanediol, 2-ethyl-2-butyl-1,3-propanediol, neopentyl glycol hydroxypivalate, diethylene glycol, triethylene glycol and mixtures thereof. 11. The wound dressing of claim 1, wherein the wound dressing is a single layer with a thickness ranging from 10 to 5000 microns. 12. The wound dressing of claim 1, wherein the wound dressing is substantially transparent. 13. The wound dressing of claim 1, wherein nitric oxide is released from the hydrated dressing surface at a flux in a range of 0.1 pmol NO cm−2 to 100 pmol NO cm−2. 14. The wound dressing of claim 1, wherein nitric oxide is stored in the dressing in an amount in a range of 100 pmol NO cm−2 to 1000 pmol NO cm−2. 15. The wound dressing of claim 1, wherein nitric oxide is stored in the dressing in an amount in a range of 1 nmol NO cm−2 to 10 μmol NO cm−2. 16. A method for treating a wound comprising applying a wound dressing of claim 1 to a wound. 17. The method of claim 16, further comprising debriding the wound prior to applying the wound dressing. 18. The method of claim 16, further comprising performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing. 19. The method of claim 18, whereby the negative pressure wound therapy device and the wound dressing of claim 1 is configured as one device. 20. The method of claim 16, further comprising treating the wound with an anti-biofilm agent prior to or in combination with the application of the wound dressing. 21. The wound dressing of claim 1, wherein the wound dressing comprises a first layer that, when applied to a wound bed, contacts the wound bed and is non-interactive with the wound bed, anda second layer on the first layer. 22. The wound dressing of claim 21, wherein the first layer is substantially free of NO-releasing macromolecules and comprises at least one therapeutic agent, and wherein the second layer comprises the polymer matrix having NO-releasing polysiloxane macromolecules therein. 23. The wound dressing of claim 1, wherein at least 95% of the NO is retained in the wound dressing after one week at 25° C. 24. The wound dressing of claim 1, wherein greater than 98% of the NO-releasing polysiloxane macromolecules are retained in the wound dressing after incubation of the wound dressing in phosphate buffered saline at pH 7.4 for 48 hours at 37° C. 25. A method of forming a wound dressing, comprising: combining NO-releasing polysiloxane macromolecules and at least one monomer, wherein the NO-releasing polysiloxane macromolecules are NO-releasing particles that have a molar mass of at least 500 Da and a diameter in a range of 0.1 nm to 100 μm; andpolymerizing the at least one monomer to form a polymer matrix comprising the NO-releasing polysiloxane macromolecules, wherein the polymer matrix comprises a polyurethane foam. 26. The method of claim 25, wherein the monomer is polymerized by photocuring. 27. The method of claim 25, wherein the polymerization occurs by a method comprising depositing liquid monomer, NO-releasing polysiloxane macromolecules and an initiator; and polymerizing the liquid monomer. 28. The method of claim 25, wherein combining NO-releasing polysiloxane macromolecules and at least one monomer comprises dispersing the NO-releasing macromolecules in a mixture of foam forming monomers; wherein polymerizing the at least one monomer to form a polymer matrix comprises polymerizing the foam forming monomers to form a polymer, and foaming the polymer to form the polymer matrix. 29. The method of claim 28, wherein the polymer foam is formed by the use of a blowing agent selected from at least one of the group consisting of carbon dioxide, hydrohalo-olefins and alkanes. 30. The method of claim 29, wherein the blowing agent includes carbon dioxide generated from carbamates that are formed from alkanolamines selected from at least one of the group consisting of 2-(2-aminoethylamino)ethanol, (3-[(2-aminoethyl)amino)]propanol), (2-[(3-aminopropyl)amino]ethanol), (1-[(2-aminoethypamino]-2-propanol, (2-[(3-aminopropyl)methylamino]ethanol, 1-[(2-amino-1-methylethyl)amino]-2-propanol, 2-[((2-amino-2-methylpropyl)amino]-2-methyl-1-propanol, 2-[(4-amino-3-methylbutypamino]-2-methyl-1-propanol, 17-amino-3,6,9,12,15-pentaazaheptadecan-1-ol and 3,7,12,16-tetraazaoctadecane-1,18-diol. 31. The method of claim 25, wherein combining NO-releasing polysiloxane macromolecules and at least one monomer comprises reacting functional groups on the NO-releasing macromolecules with at least one foam forming monomer; wherein polymerizing the at least one monomer to form a polymer matrix comprises polymerizing the foam forming monomers to form a polymer, and foaming the polymer to form the polymer matrix. 32. A wound dressing kit, comprising one or more of a first wound dressing that releases low concentrations of nitric oxide over 0 to 7 days in the range of 0.5 pmol NO cm−2 s−1 to 20 pmol NO cm−2 s−1 upon initial application to the patient;a second wound dressing that releases intermediate concentrations of nitric oxide over 0 to 7 days in the range of 20 pmol NO cm−2 s−1 to 1000 pmol NO cm −2 s−1 upon initial application to the patient; anda third wound dressing that releases high levels of nitric oxide for 0 to 48 hours in the range of 1 nmol NO cm−2 s−1 to 1 μmol NO cm−2 s−1 upon initial application to the patient,wherein each of the wound dressings comprises a polymer matrix and NO-releasing polysiloxane macromolecules within the polymer matrix, wherein the NO-releasing polysiloxane macromolecules are NO-releasing particles that have a molar mass of at least 500 Da and a diameter in a range of 0.1 nm to 100 μm and the polymer matrix comprises a polyurethane foam, and wherein each wound dressing is non-toxic and can stably store nitric oxide. 33. The wound dressing kit of claim 32, wherein the second wound dressing further includes an anti-inflammatory agent. 34. The wound dressing kit of claim 32, wherein the third wound dressing further includes an anti-microbial agent.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.